Extracorporeal Membrane Oxygenation for Diffuse Alveolar Hemorrhage Caused by Idiopathic Pulmonary Hemosiderosis: A Case Report and a Review of the Literature

Matsumoto, Shotaro; Nakagawa, Satoshi

doi:10.1055/s-0039-1679904

Cited by 9 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rescue therapy with extracorporeal membrane oxygenation has been successfully performed in patients with acute respiratory failure in the setting of massive DAH. 78 Patients with end-stage lung disease due to recurrent bleeding leading to the development of pulmonary fibrosis may be candidates for lung transplantation. However, there may be a risk of recurrence of IPH in the transplanted lungs.…”

Section: Treatmentmentioning

confidence: 99%

Updates in idiopathic pulmonary hemosiderosis in 2022: A state of the art review

Saha

Aiman

Chong

et al. 2022

Pediatric Pulmonology

View full text Add to dashboard Cite

This manuscript reports the recent advances in idiopathic pulmonary hemosiderosis (IPH), a rare cause of diffuse alveolar hemorrhage in children and adults. This narrative review of the literature summarizes different aspects of IPH, including proposed pathogenesis, patient demographics, clinical and radiological characteristics, treatment, and prognosis. Additionally, the association between Celiac Disease (CD) and IPH is carefully evaluated. IPH is a frequently misdiagnosed disease. The delay in the diagnosis of IPH is often significant but fortunately, appears to have decreased in recent years. IPH in adults and children have distinct demographic preferences. The autoantibodies are common in IPH but with a definite difference between the adult and pediatric populations. The definitive diagnosis of IPH requires lung biopsy and careful exclusion of all competing diagnoses, even with lung biopsy showing bland pulmonary hemorrhage. The presence of nonspecific inflammatory cells or lymphoid aggregates may suggest a secondary immunologic phenomenon and needs careful evaluation and follow-up. A substantial number of patients suffer from coexisting CD, also known as Lane−Hamilton syndrome (LHS), and all patients with IPH need to be evaluated for LHS by serology. Although strict gluten free diet can manage the majority of patients with LHS, other patients generally require immunosuppressive therapy. The corticosteroids are the backbone of IPH therapy. Recently utilized experimental treatment options include mesenchymal stem cell transplant, liposteroid and bronchial artery embolization. The immunosuppression should be adjusted to achieve optimal disease control. Patients may progress to endstage lung disease despite all measures, and lung transplantation may be the only viable option.

show abstract

Section: Treatmentmentioning

confidence: 99%

Updates in idiopathic pulmonary hemosiderosis in 2022: A state of the art review

Saha

Aiman

Chong

et al. 2022

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…An 8‐year‐old girl, 18 with a history of asthma and iron deficiency anemia, presented with cough, wheeze, hemoptysis, and severe hypoxemia (room air saturation 68%). Despite antibiotic and corticosteroids therapy, the patient deteriorated and required aggressive medical support and two episodes of ECMO over a period of 2 weeks.…”

Section: Introductionmentioning

confidence: 99%

Congenital interstitial lung diseases: What the anesthesiologist needs to know

Bertolizio

Engelhardt

Veyckemans

2021

Pediatric Anesthesia

View full text Add to dashboard Cite

Congenital interstitial lung diseases can affect both adults and children. Pediatric congenital interstitial lung diseases generally carry high risk for morbidly and mortality and include congenital alveolar capillary dysplasia with misalignment of pulmonary veins, congenital alveolar dysplasia, acinar dysplasia, congenital pulmonary lymphangiectasis, diffuse pulmonary lymphangiomatosis, neuroendocrine cell hyperplasia of infancy, pulmonary hemosiderosis, pulmonary alveolar proteinosis, and pulmonary interstitial glycogenosis. Given their usual non-specific clinical presentation, they are frequently misdiagnosed and recognized late, particularly in children who have been apparently healthy for several years (eg, diffuse pulmonary lymphangiomatosis). Some diseases have a very poor prognosis, whereas others have a benign course with appropriate treatment. The current manuscript reviews congenital interstitial lung diseases that typically affect neonates and young children and may be encountered by the pediatric anesthesiologist.

show abstract

Proposed Pathogenesis of Diffuse Alveolar Hemorrhage in Idiopathic Pulmonary Hemosiderosis

Saha¹,

Chong

Saha

et al. 2022

Lung

View full text Add to dashboard Cite

Extracorporeal Membrane Oxygenation for Diffuse Alveolar Hemorrhage Caused by Idiopathic Pulmonary Hemosiderosis: A Case Report and a Review of the Literature

Cited by 9 publications

References 29 publications

Updates in idiopathic pulmonary hemosiderosis in 2022: A state of the art review

Updates in idiopathic pulmonary hemosiderosis in 2022: A state of the art review

Congenital interstitial lung diseases: What the anesthesiologist needs to know

Proposed Pathogenesis of Diffuse Alveolar Hemorrhage in Idiopathic Pulmonary Hemosiderosis

Contact Info

Product

Resources

About